Comprehensive evaluation for systemic sclerosis (SSc) when suspicion for SSc is high and patient presents with features of overlap syndrome. For patients with distinct features of SSc, order Criteria Systemic Sclerosis Panel (3000479).
Qualitative Immunoblot/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Multiplex Bead Assay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 3 mL serum to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
|0050599||Scleroderma (Scl-70) (ENA) Antibody, IgG||
|0050470||Smith/RNP (ENA) Antibody, IgG||
|3000082||Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA||Less than 1:80|
|2012173||Fibrillarin (U3 RNP) Antibody, IgG||Negative|
|2003040||PM/Scl-100 Antibody, IgG by Immunoblot||Negative|
|2001601||RNA Polymerase III Antibody, IgG||
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Panel includes: Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA, Scleroderma (Scl-70) (ENA) Antibody, IgG, RNA Polymerase III Antibody, IgG, Smith/RNP (ENA) Antibody, IgG, Fibrillarin (U3 RNP) Antibody, IgG, PM/Scl-100 Antibody, IgG by Immunoblot.
86039; 86235 x4; 83516
|Component Test Code*||Component Chart Name||LOINC|
|0050470||Smith/RNP (ENA) Ab, IgG||33983-8|
|0050599||Scleroderma (Scl-70) (ENA) Antibody, IgG||47322-3|
|2001602||RNA Polymerase III Antibody, IgG||79182-2|
|2003041||PM/Scl 100 Antibody, IgG||81732-0|
|2012174||Fibrillarin (U3 RNP) Ab, IgG||49963-2|
|3000090||Antinuclear Antibody (ANA), HEp-2, IgG||21424-7|
|3000096||ANA Interpretive Comment||49311-4|